Efficacy Study according to system of devices of Rayonex Biomedical at the Fraunhofer Institute (FEP) in Dresden by Prof. Dr. med. habil. E. W. J. Mikus.
Since 1982, Rayonex Biomedical GmbH, based in the Sauerland Pyramids, has been researching, developing and producing in the field of bioresonance according to Paul Schmidt, named after the founder of Rayonex.
As early as 1976, he postulated that human and animal organs could be activated or stimulated with specific frequency spectra specific to them. To date, Rayonex has conducted many application observations and studies on the effectiveness of the medical products produced. All of them with good results.
In the end, however, it must be critically said that in all the studies carried out, the placebo effect – i.e. the therapeutic success based on imagination – could not be completely ruled out.
For this reason, Rayonex, supported by the Vereinigung zur Förderung der Schwingungsmedizin e. V. (Association for the Promotion of Vibrational Medicine), was already looking for a scientifically validated method to prove the effectiveness of the bioresonance devices produced.
The result is summarised in the final report of the Fraunhofer Institute (FEP) as follows:
Treated and untreated cell cultures were examined for their cell morphology. The study states: “Analogous to the fibroblasts, the keratinocytes also show no morphological differences in cell appearance between the individual experimental groups”.
This is a very valuable statement for every patient, every therapist and for vibrational medicine. Because with this, bioresonance according to Paul Schmidt and the RAH live up to their claims of a therapy that has few side effects and is effective at the same time.
Cells treated with bioresonance according to Paul Schmidt and RAH (right) show no morphological changes compared to untreated cells (left).
Difference in efficiency
Rayocomp PS 1000 polar and PS 10
Since the Rayocomp PS 10 is much smaller, it can be assumed that its effect is also smaller than that of a Rayocomp PS 1000 polar. The study found that the PS 1000 is indeed “stronger” than a Rayocomp PS 10 (by approx. 2 % in absolute terms, by approx. 15 % in relative terms, see graphs below).
The postulate of Paul Schmidt
In the study, the effect on fibroblasts as well as on keratinocytes was examined. With one frequency spectrum, a good effect on fibroblasts was found, but not on keratinocytes. With another frequency spectrum, however, keratinocytes could then be stimulated, but not fibroblasts.
This result supports the postulate put forward by Paul Schmidt in 1976 that every organ, every tissue and thus every cell structure has its own frequency spectrum with which it can be stimulated. This is why the differentiation of the programmes contained in the RAH, which are all based on different frequency spectra, is so important.